Breaking News Instant updates and real-time market news.

PTI

Proteostasis

$2.44

0.06 (2.52%)

07:11
12/02/19
12/02
07:11
12/02/19
07:11

Proteostasis regains compliance with Nasdaq listing standards

Proteostasis announced that it received a letter dated November 27 from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that it has regained compliance with the requirement of The Nasdaq Global Market to maintain a minimum bid price of $1.00 per share. The letter noted that as of November 26, the company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the matter closed.

  • 03

    Dec

PTI Proteostasis
$2.44

0.06 (2.52%)

03/26/19
HCWC
03/26/19
NO CHANGE
Target $15
HCWC
Buy
Proteostasis regiments warrant further investigation, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says it was his hope that the Proteostasis (PTI) compounds would generate a 10 ppFEV1 improvement and provide either a legitimate competitor for Vertex (VRTX) or identification of molecules that could serve as possible add-ons to other shelved or early development modulators. Factually, none of the dose cohorts measured at either seven-day or 14-days after treatment generated a 10 ppFEV1 improvement, Fein tells investors in a research note. However, due to the complete lack of any competition to the Vertex "strangle-hold" on the cystic fibrosis landscape as well as the "apparent if not overwhelming desire," at least outside of the U.S., for a second option, the Proteostasis regiments warrant further investigation, says the analyst. He believes yesterday's data may provide an opportunity in more severe cystic fibrosis patients. Fein keeps a Buy rating on Proteostasis with a $15 price target. The stock closed yesterday down 68%, or $2.76, to $1.31.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $5
PIPR
Overweight
Proteostasis price target lowered to $5 from $10 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target on Proteostasis to $5 after its Q1 results that disclosed the company's $105M cash position and also to reflect its recently reported disappointing Phase 1 TripleRx data in homozygous F508del CF patients. The analyst maintains his Overweight rating on the stock but also lowers his estimate for Proteostasis' proprietary TripleRx regimen in the U.S. at $128M vs. $293M prior view.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $4
PIPR
Overweight
Piper says Proteostasis guiding to TripleRx CF data sooner than expected
Piper Jaffray analyst Edward Tenthoff noted that Proteostasis said has completed enrollment of the Phase 2 study of 60 f508del cystic fibrosis patients ahead of schedule and is now guiding to top-line data by year-end 2019, which is ahead of the prior expectation of the first quarter of 2020. If it generates positive data for the triple combo of amplifier PTI-428 with CFTR corrector PTI-801 and potentiator PTI-808, Proteostasis could initiate a Phase 3 trial next year, said Tenthoff, who keeps an Overweight rating and $4 price target on Proteostasis shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$347.25

7.78 (2.29%)

10:38
12/10/19
12/10
10:38
12/10/19
10:38
Recommendations
Tesla analyst commentary  »

Tesla price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 07

    Jan

AXTA

Axalta Coating

$29.81

-0.41 (-1.36%)

10:35
12/10/19
12/10
10:35
12/10/19
10:35
Options
Axalta Coating put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
12/10/19
12/10
10:30
12/10/19
10:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NLOK

NortonLifeLock

$26.29

0.86 (3.38%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Options
NortonLifeLock call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
UBS alternative energy windham to hold an analyst/industry conference call »

Alternative Energy &…

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
JPMorgan oil & gas analysts to hold an analyst/Industry conference call »

Large Cap Oil & Gas…

OMCL

Omnicell

$80.19

0.16 (0.20%)

10:25
12/10/19
12/10
10:25
12/10/19
10:25
Conference/Events
Omnicell to host investor & analyst day »

Investor & analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

, MCD

McDonald's

$194.64

-0.07 (-0.04%)

10:19
12/10/19
12/10
10:19
12/10/19
10:19
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

QSR

Restaurant Brands

$66.80

0.8 (1.21%)

MCD

McDonald's

$194.64

-0.07 (-0.04%)

SBUX

Starbucks

$87.36

1.08 (1.25%)

WEN

Wendy's

$21.59

-0.13 (-0.60%)

CMG

Chipotle

$822.75

-4.81 (-0.58%)

DNKN

Dunkin' Brands

$76.03

-0.2 (-0.26%)

EAT

Brinker

$41.77

-0.92 (-2.16%)

DPZ

Domino's Pizza

$286.82

0.23 (0.08%)

YUM

Yum! Brands

$98.95

-0.04 (-0.04%)

TXRH

Texas Roadhouse

$55.93

-0.22 (-0.39%)

ARAV

Aravive

$12.19

0.89 (7.88%)

BORR

Borr Drilling

$6.80

0.2 (3.03%)

AAXN

Axon

$72.49

0.22 (0.30%)

ZM

Zoom Video

$64.98

-0.94 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 16

    Dec

NFLX

Netflix

$295.83

-6.65 (-2.20%)

, JPM

JPMorgan

$133.55

-0.9 (-0.67%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

NFLX

Netflix

$295.83

-6.65 (-2.20%)

JPM

JPMorgan

$133.55

-0.9 (-0.67%)

MKC

McCormick

$170.54

-2.155 (-1.25%)

CSX

CSX

$69.59

-0.82 (-1.16%)

VTR

Ventas

$56.78

-0.72 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

, RDFN

Redfin

$20.98

0.21 (1.01%)

10:18
12/10/19
12/10
10:18
12/10/19
10:18
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

PH

Parker-Hannifin

$201.96

0.49 (0.24%)

RDFN

Redfin

$20.98

0.21 (1.01%)

MNRO

Monro

$78.70

4.24 (5.69%)

AGRO

Adecoagro

$7.98

0.47 (6.26%)

OI

Owens-Illinois

$10.51

0.22 (2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/10/19
12/10
10:17
12/10/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/10/19
12/10
10:16
12/10/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LK

Luckin Coffee

$30.72

0.35 (1.15%)

10:15
12/10/19
12/10
10:15
12/10/19
10:15
Options
Luckin Coffee put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTT

Qutoutiao

$2.70

-0.16 (-5.59%)

10:14
12/10/19
12/10
10:14
12/10/19
10:14
Hot Stocks
Qutoutiao sinks after short report claims 74% of sales are 'fake' »

Shares of Qutoutiao moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$43.80

0.515 (1.19%)

10:12
12/10/19
12/10
10:12
12/10/19
10:12
Conference/Events
Smartsheet management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

SFIX

Stitch Fix

$27.20

2.03 (8.07%)

10:11
12/10/19
12/10
10:11
12/10/19
10:11
Conference/Events
Stitch Fix management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

CHWY

Chewy

$24.93

0.76 (3.14%)

10:10
12/10/19
12/10
10:10
12/10/19
10:10
On The Fly
Investors weigh Chewy's IPO lockup expiry against better than expected sales »

Shares of Chewy.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

RST

Rosetta Stone

$16.55

0.075 (0.46%)

10:09
12/10/19
12/10
10:09
12/10/19
10:09
Conference/Events
Rosetta Stone management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RPAI

Retail Properties of America

$13.90

0.02 (0.14%)

10:07
12/10/19
12/10
10:07
12/10/19
10:07
Conference/Events
Retail Properties of America management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 19

    Feb

PYPL

PayPal

$104.01

0.25 (0.24%)

10:06
12/10/19
12/10
10:06
12/10/19
10:06
Conference/Events
PayPal management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

QTT

Qutoutiao

$2.75

-0.11 (-3.85%)

10:06
12/10/19
12/10
10:06
12/10/19
10:06
Hot Stocks
Breaking Hot Stocks news story on Qutoutiao »

Qutoutiao drops 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PWFL

PowerFleet

$5.90

(0.00%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

QTT

Qutoutiao

$2.74

-0.12 (-4.20%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Periodicals
Breaking Periodicals news story on Qutoutiao »

Wolfpack Research says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$18.86

-0.06 (-0.32%)

10:05
12/10/19
12/10
10:05
12/10/19
10:05
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
12/10/19
12/10
10:05
12/10/19
10:05
General news
The FOMC began its 2-day meeting »

The FOMC began its 2-day…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.